Clindamycin phosphate

Cat. No.: HY-B1064 CAS No.: 24729-96-2

Molecular Formula: $C_{18}H_{34}ClN_2O_8PS$

Molecular Weight: 504.96

Target: Bacterial; Antibiotic; Parasite

Pathway: Anti-infection

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 2 years

> -20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

 $H_2O: 100 \text{ mg/mL}$ (198.04 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| | 1 mM | 1.9804 mL | 9.9018 mL | 19.8035 mL |
| | 5 mM | 0.3961 mL | 1.9804 mL | 3.9607 mL |
| | 10 mM | 0.1980 mL | 0.9902 mL | 1.9804 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 50 mg/mL (99.02 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis^{[1][2][3]}.

IC₅₀ & Target

Antibiotic, Bacterial^{[1][3]}

CUSTOMER VALIDATION

- EBioMedicine. 2022 Apr;78:103943.
- bioRxiv. 2024 Jan 18.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Li H, et al. Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. Eur J Clin Pharmacol. 2017 Feb;73(2):251-253.

[2]. Hayashi N, et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study. J Dermatol. 2018 Aug;45(8):951-962.

[3]. A. Dupre, et al. Proof of concept study of a novel bioadhesive clindamycin phosphate 2% vaginal gel to treat bacterial vaginosis. Clin. Exp. Obstet. Gynecol. 2020, 47(4), 516–518

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA